Antibodies are important tools for a broad range of applications due to their high specificity and ability to recognize virtually any target molecule. However, in order to be practically useful, antibodies must be highly stable and bind their target antigens with high affinity. We present a combinatorial approach to generate high-affinity, highly stable antibodies through the design of stable frameworks, specificity grafting and maturation via somatic hypermutation in vitro. By collectively employing these methods, we have engineered a highly stable, high-affinity, full-length antibody with a T m over 908 8 8 8 8C that retains significant activity after heating to 908 8 8 8 8C for 1 h, and has ∼95-fold improved antigen-binding affinity. The stabilized IgG framework is compatible with affinity maturation, and should provide a broadly useful scaffold for grafting a variety of complementarity-determining region loops for the development of stable antibodies with desired specificities.
Introduction
Antibodies are able to recognize a wide variety of antigens with extremely high specificity, making them ideal tools for a broad range of therapeutic, diagnostic and industrial applications. Antibodies used for therapeutic purposes must have good pharmaceutical properties and often a long serum halflife, facilitated both by thermal stability and resistance to aggregation (Carter and Merchant, 1997; Willuda et al., 1999) . Industrial applications may require antibodies that retain function following exposure to high temperatures, organic solvents and other stresses not found in the in vivo environment (Dooley et al., 1998) . Antibody-based biosensors, for example, provide the most reliable detection capability across a broad range of targets, but require high stability and a long shelf life in order to be practically useful (Conroy et al., 2009) . Despite their potential, few antibodies currently possess ideal biophysical properties, and there has been much recent focus on understanding and improving the stability of antibodies and antibody fragments (Ewert et al., 2003b; Rothlisberger et al., 2005; Monsellier and Bedouelle, 2006; Garber and Demarest, 2007; Jordan et al., 2009; Caravella et al., 2010) . A highly stable antibody framework that can be applied across multiple antigen specificities while maintaining, or improving affinity, is desirable for the efficient application of antibodies to these expanding technologies.
Numerous knowledge-based approaches to engineering antibody stability have been described (Worn and Pluckthun, 2001; Monsellier and Bedouelle, 2006) . Grafting complementaritydetermining regions (CDRs) of defined specificity onto known stable frameworks is a proven rational approach to antibody stabilization (Jung and Pluckthun, 1997; Jung et al., 1999) . However, CDR grafting frequently results in a loss of binding affinity, especially when grafting into distantly related frameworks (Jones et al., 1986; Queen et al., 1989; Honegger et al., 2009) . This leads to a need for extensive affinity maturation to restore antigen-binding activity.
A second approach for engineering antibody stability, consensus design, utilizes the natural variation present within antibody variable domain sequences to identify non-canonical residues within the candidate antibody. Introduction of consensus residues into structurally equivalent positions in the candidate antibody has been demonstrated to improve the stability of immunoglobulin (IgG) V regions (Steipe et al., 1994; Chowdhury et al., 1998) , and has been applied more broadly to stabilize non-IgG proteins (Steipe, 2004) . There remains the possibility, however, that consensus design will negatively impact the binding affinity of the stabilized domain.
Introducing non-native disulfide bonds is another wellestablished method of protein stabilization (Matsumura et al., 1989; Trivedi et al., 2009) . Native antibodies gain much of their intrinsic stability through highly conserved intra-domain disulfides occurring in each of their folded domains (Goto and Hamaguchi, 1979; Frisch et al., 1996) . Antibody fragments lacking these disulfides have been generated for functional expression in the reducing environment of the prokaryotic cytoplasm; however, significant stabilization is required to compensate for the missing disulfide bonds (Martineau et al., 1998; Proba et al., 1998) . Inter-domain disulfide bonds have been introduced between the V H and V L domains to enhance stability of single-chain Fv (scFv) antibody fragments with some success (Reiter et al., 1994; Young et al., 1995) . A recent study identified a novel, naturally occurring intra-domain disulfide bond within a Camelidae-derived V HH antibody fragment that provided additional stability when transferred onto other V HH antibodies without adversely affecting antigen binding (Saerens et al., 2008) . Likewise, a disulfide bond linking N-and C-terminal b-strands of an isolated C H 2 domain has been shown to significantly increase its stability in both human and mouse (Gong et al., 2009) . These approaches, however, have not yet been applied to the more complex, full-length immunoglobulin context. Structure-based, computational design for the optimization of proteins has advanced significantly over the past decade, and provides a complement to the knowledge-based approaches described above. Demonstrated applications include the complete redesign (Dahiyat and Mayo, 1997) and thermodynamic stabilization of natural protein domains Korkegian et al., 2005) , and the creation of extremely stable novel protein structures Dantas et al., 2007) . In silico approaches have been applied to engineer antibody-like molecules with enhanced thermal and chemical stability (Jordan et al., 2009) , to reduce aggregation propensity of IgG constant domains (Chennamsetty et al., 2009) and to design antibodies with higher affinity for a given antigen (Clark et al., 2006; Farady et al., 2009) . Thermostabilization of an antibody is particularly challenging because it requires that the conformation of regions important for antigen binding, such as the CDR loops, be retained.
Each of the approaches to antibody stabilization outlined above involves the introduction of mutations that have the potential to disrupt antigen binding, necessitating a reliable method of antibody maturation to restore, or improve, the desired binding affinity. Several approaches to improve the antigen-binding characteristics of antibodies exist. These include random or directed mutagenesis of the V-domain coupled with phage, yeast and ribosome display technologies (Hoogenboom, 2005) , as well as a recently described system that couples in vitro somatic hypermutation (SHM) with mammalian cell display (Bowers et al., 2011) . Mammalian display systems offer several advantages for therapeutic antibody generation, including the ability to display functional, fully glycosylated IgGs on the cell surface, and to simultaneously select these antibodies for high expression levels as well as improved antigen-binding affinity. Furthermore, coupling mammalian display with in vitro SHM enables the selection and affinity maturation of high-affinity antibodies while minimizing the number of mutations incorporated into the starting antibody sequence in comparison with random mutagenesis strategies. This reduces the potential for incorporating mutations that negatively impact antibody stability. Such a system for affinity maturation should be highly compatible with maintaining stability of the engineered antibody.
In this study, we applied a combination of approaches to generate an extremely stable antibody with high affinity for antigen. An scFv fragment targeting the MS2 bacteriophage coat protein was selected as the starting point for this study. This antibody was selected for optimization as a part of the Defense Advanced Research Projects Agency (DARPA) Antibody Technology Program to develop stable, highaffinity antibodies for use in biosensors. CDRs from the scFv were grafted onto a human IgG framework as a first step toward developing a broadly useful stable antibody scaffold. Rational engineering and computational methods were then used to generate stabilized forms of the antibody, which allowed the generation of a highly stable scaffold. To demonstrate the compatibility of the stabilized antibody with affinity maturation, an interface-optimized variant of the initial grafted antibody was matured using SHM in vitro and mammalian cell surface display (Bowers et al., 2011) . CDR loops from the affinity matured anti-MS2 antibody variant were subsequently incorporated into the stabilized scaffold resulting in complete retention of both stability and affinity. This provides initial evidence of the potential for the stabilized scaffold to serve as a basis for CDR-grafting loops from alternate antibodies to generate high-affinity forms with enhanced biophysical characteristics.
Materials and methods

Protein expression and purification
The anti-MS2 scFv was derived by panning a library generated from mice immunized with MS2 phage, and was obtained from J.Carney (U.S. Army ECBC). Originally isolated as a Fab, the antibody fragment was converted to scFv format with a (Gly4Ser) 3 linker between V H and V L domains, expressed transiently in HEK293 c-18 cells, and purified using standard His-tag affinity and size-exclusion chromatography purification methodologies. Purified scFv was analyzed by FPLC (fast protein liquid chromatography) to ensure the absence of dimers and immediately used in assays.
Full-length human IgG antibody variants were similarly expressed transiently in HEK293 c-18 cells, purified using a protein A/G agarose resin (Thermo Scientific), washed with 6 column-volumes of 1Â phosphate-buffered saline (PBS), pH 7.4, and eluted with 100 mM glycine, pH 3.0, followed by buffer exchange into 1Â PBS, pH 7.4. All mutagenesis was carried out using the QuickChange II site-directed mutagenesis kit (Agilent Technologies). The Kabat numbering scheme is employed throughout this manuscript.
The MS2 phage coat protein antigen was expressed as a dimer containing a single point mutation, W82R, known to inhibit viral capsid assembly (Peabody and Ely, 1992) . MS2 antigen was expressed in HEK293 c-18 cells; constructs included a His-tag both with and without a C-terminal Wasabi fluorescent protein (WFP) tag, and were purified by His-tag affinity purification. The WFP tag was added to the MS2 coat protein antigen in order to improve its solution behavior as evidenced by reduced non-specific binding in fluorescence-activated cell sorting (FACS) profiles.
Thermostability measurements
Differential scanning calorimetry. Thermal unfolding profiles of anti-MS2 antibody variants were measured by differential scanning calorimetry (DSC) using the VP-Capillary DSC system (GE Healthcare). All antibodies were tested in PBS, pH7.4 at protein concentrations ranging from 0.7-1.0 mg/ml at a scan rate of 18C/minute. The final stabilized antibody, APE979, was also tested in two histidine-based buffers containing 20 mM histidine, pH 6.5 or 7.0, 230 mM sucrose and 0.02% Tween 80. Samples were heated from 20 to 908C or 20 to 1108C. Data analysis was performed using Origin 7 software. Transition mid-point values (T m ) were determined from the thermogram data using the non-two-state model which employs the LevenbergMarquardt non-linear least-square method. Total calorimetric heat change values (DH) were determined by calculating the total area under a given antibody thermogram.
Thermofluor assay. Thermofluor assay analysis was carried out using the ProteoStat Thermal Shift Stability Assay (Enzo Life Sciences). This assay measures thermostability using a fluorescent dye that binds to hydrophobic patches exposed as the protein unfolds. Antibody concentration was normalized to 0.2 mg/ml and fluorescence was read using the LightCycler 480 system (Roche) at 480 nm excitation and 610 nm emission. Samples were heated from 20 to 998C at 58C/minute. The aggregation temperature measured by this assay does not exactly match T m by DSC, but the rank-order of protein stability was found to be highly consistent between the two methods.
Affinity characterization of antibody variants
Kinetic analysis was performed using a Biacore T200 (GE Healthcare). For antibody fragments in scFv format, 200 response units (RU) of MS2 was immobilized (CM5 chip) and samples were tested in a concentration range from 10-fold above the K D to 10-fold below the K D ; scFv was passed over the surface for 600 s at a flow rate of 30 ml/min to minimize mass transport, and allowed to dissociate for 900 s. For full-length IgGs, a capture assay was used to allow accurate assessment of antibody affinity and to minimize potential avidity effects due to the bivalent nature of the full-length antibody. Antibody (1 mg/ml) was captured on a surface of 3000 RU mouse anti-human IgG Fc for 60 s at a flow rate of 10 ml/min, resulting in low capture levels between 15 and 40 RU. Antigen was flowed over the captured IgG surface for 600 s at 30 ml/min, again using a range from 10-fold above to 10-fold below the K D in each case. Antigen was allowed to dissociate for 600 s. Surfaces were regenerated using 3 M MgCl 2 . Association and dissociation kinetic values (k a and k d ) were determined from a best fit of the data with the 1 : 1 Langmuir global fitting procedure to sensorgrams using the Biacore T200 Evaluation Software, version 1.0.
Thermal challenge activity assays were performed by heating anti-MS2 antibody variants for 1 hour at a defined temperature (70 -898C) and then cooling to 48C. Heat-treated samples were compared with unheated samples for each antibody variant using Biacore analysis. Percent antigen-binding activity was determined by comparing experimental R max values for each sample to that of the unheated control.
Fc receptor binding was measured by immobilizing 1000 RU of soluble CD64 (R&D Systems) on a CM5 chip and testing antibody samples at 500 and 250 nM. Relative binding affinities were determined by comparing R max values between antibody samples.
Computational design method
RosettaDesign was used as described (Kuhlman and Baker, 2000) , with designs carried out in two rounds Korkegian et al., 2005) . Backbone templates for heavy chain variable region design were PDB ID 3KDM and 2VXS, and PDB ID 1T66, 1HPO and 2H1P served as templates for light chain variable region design, each selected based on sequence homology to the originating scFv. Residues in the CDR loops and all Cys residues were excluded from the design. Round 1 of each design allowed the remaining residues to change to all amino acids except Cys, searching a limited side chain conformational database containing rotameric models varied only around the first chi angle. A total of 100 independent runs were performed generating 100 sequences each. The second round limited the search only to those amino acids chosen during the first round. A larger rotamer library was used in this round that included chi-2 angle rotations. One hundred sequences were generated in each design round. Sequences that produced the lowest energy were analyzed, and the most frequently observed mutations giving the greatest energy improvement were chosen for testing in the context of the anti-MS2 antibody.
The backrub application of RosettaDesign was used to evaluate the compatibility of disulfide bond formation between V H residues 49 and 69, and to predict the effect of this substitution on CDR loop positioning. This application of RosettaDesign allows flexible backbone modeling within a defined radius surrounding the desired substitutions (Smith and Kortemme, 2008) . The backrub radius was set to 6 Å around the S49C and I69C point mutations. The structure PDB ID 2VXS, derived from V H 3 -23, was used as a template for the design to generate 10 output structural models.
Mammalian cell display and in vitro somatic hypermutation
A stable HEK293 c18 cell line expressing the anti-MS2 antibody APE556 modified with a C-terminal transmembrane domain on the heavy chain for surface expression was generated as described (Bowers et al., 2011) . Antibody surface expression was confirmed by staining with FITC-labeled goat-anti-human CH1. Cells were transiently transfected with an activation-induced cytidine deaminase (AID) expression vector for mutagenesis. After 5 days, cells were subjected to selection by FACS using fluorescently labeled MS2 antigen. Co-expression of heavy and light chain genes with the AID enzyme induced SHM in the antibody resulting in in situ generation of genetic diversity in the antibody variable domain. Cells were stained by incubating for 30 min at 48C with MS2-DyLight-649 or MS2-WFP-DyLight-649 starting at 30 nM for early sorts and decreasing to 40 pM in the later sort rounds. To stain for IgG expression, FITC-Goat anti-Human IgG was added (1 : 2000) for 30 min at 48C. The highest antigen-binding cells, normalized for antibody expression, were sorted using a BD Influx cell sorter (BD Biosciences). Sequencing of 30 heavy chains and light chains from sorted cells subsequent to each FACS round revealed enriching SHM-induced mutations. High-throughput sequencing was additionally utilized to generate over 100 000 heavy chain sequences for pre-and post-round five sort populations as described (Bowers et al., 2011) .
In order to further explore SHM diversity in the light chain, four libraries of 100 members each were constructed to recombine frequently observed SHM events. Corresponding amino acid substitutions were incorporated into the CDR loops of the CDR-grafted anti-MS2 antibody. For example, Library 1 consisted of the following variations: Q27QEL, S27eSTNGRDE and H93HRLYNQ. Mutations were generated by overlap extension PCR using degenerate primers. Individual clones were sequenced, and HEK293 cultures were transiently transfected with heavy chain/light chain pairs in 96-well format. To rank variant antibodies based on K D , supernatants were directly screened by Biacore 4000 using direct capture of secreted antibodies to measure 2 Â 2. The best variants (K D 10 nM) were re-transfected on a larger scale, purified and analyzed by Biacore T200 to obtain full binding kinetics data.
Results
CDR grafting onto stable human frameworks
With the goal of generating a broadly useful IgG scaffold, stable basis V H and V L domains were selected as a starting point for CDR grafting from the anti-MS2 scFv selected for optimization in this study. Previous studies have shown V H 3 to be the most stable family of human V H domains (Ewert et al., 2003b) , and V H 3-23 is one of the most commonly utilized human germline heavy chain variable regions (Glanville et al., 2009 ). Although there is less variation among the V L domains, V k 1, V k 2, and V k 3 domains are among the most stable of eight human V L domain subgroups (Ewert et al., 2003b) . Alignment of the mouse-derived, anti-MS2 scFv showed that the human V H and V L regions with highest homology were V H 3 and V k 2 families. Given these data, germline variable regions hV H 3-23 and hV k 2D-30, each with 80% identity to the scFv excluding the CDR3, were selected as the starting point for grafting and stabilization (Fig. 1) . CDR1, CDR2 and CDR3 were grafted into the hV H 3-23 and hV k 2D-30 frameworks and formatted as full-length immunoglobulin using stable human constant regions, IgG1z kappa (Demarest et al., 2004; Garber and Demarest, 2007) .
DSC analysis of the initial grafted antibody, APE443, gave a typical IgG curve with three unfolding transitions (Fig. 2b) . A direct comparison of variable domains revealed a modest 2.68C improvement in T m relative to the starting scFv (Fig. 2a vs. b ; Table I ). However, it is important to note that the scFv and APE443 are expressed as different antibody formats which may impact their relative T m values. Binding affinity measurements for the scFv were obtained by surface immobilization of antigen, whereas affinity measurements for IgGs were determined by an IgG capture assay using a low-density surface to avoid potential avidity effects of the bivalent full-length antibody. Although the K D values are not directly comparable, kinetic analysis suggests that grafting into the human V regions resulted in a modest loss of MS2 antigen binding affinity relative to the originating scFv, with K D values of 29 and 84 nM, respectively ( Fig. 2c and d) . Reported K D values are indicative of binding affinity of antibody variants for the dimeric MS2 antigen. The dimeric nature of the antigen may result in some residual avidity in the assay; therefore, K D values should be considered as relative values.
Improving the V H /V L heterodimer interface
The interface between heavy and light chain variable domains can significantly impact both the stability and affinity of an antibody (Ewert et al., 2003b) . Three important interface residues were identified in the V L that differed between the specificity donor (scFv) and acceptor (hV k 2D-30) using the method outlined byEwert et al. (2004) . Residues F36Y, R46L and Y87F were changed back to the original scFv sequence (Fig. 3a) . DSC analysis of this antibody, APE556, gave an 8.48C increase in Fab T m over the initial graft ( Fig. 3b ; Table I ). In addition, improvement of the V H /V L interface restored MS2 binding affinity back to the wild-type K D ( Fig. 3c ; Table I ). Fig. 1 . Sequence alignment of (a) V H and (b) V L domains from anti-MS2 scFv to the closest mouse and human germline V regions. CDR1 and CDR 2 sequences are highlighted; CDR3 was excluded from the alignment. Residues are numbered according to the Kabat scheme for each V-region. Human V H 3-23 and V k 2D -30 were chosen as acceptor frameworks for the CDR graft of anti-MS2 specificity. Note that the scFv light chain is 99% germline. 
Disulfide bond engineering
V H stabilization. A naturally occurring, non-conserved disulfide bond within a single-domain antibody fragment derived from a Camelidae-specific heavy chain antibody (V HH ) was recently described, and shown to have a stabilizing effect when transferred to other V HH fragments (Saerens et al., 2008) . To determine whether such a disulfide bond could be similarly stabilizing in the human IgG context, the amino acid sequence of this single-domain antibody was aligned with the MS2 antibody V H . Homologous positions S49 and I69 were identified as candidates for disulfide bond insertion. These framework residues occur on opposing b-strands, similar to the conserved intra-V H disulfide bond that connects framework residues C22 and C92, and is buried within the hydrophobic core of the V-region fold (Fig. 4a) .
Computational methods were employed to assess whether these positions were likely to accommodate a disulfide bond. The Disulfide by Design algorithm confirmed the appropriate geometry for intra-domain disulfide bond formation between residues I49 and S69 (Dombkowski, 2003) . Furthermore, RosettaDesign predicted Cys substitutions at these positions to form a disulfide bond within the V H , resulting in a significant energy improvement with no impact on CDR loop conformation. Together, these analyses suggested that addition of this disulfide bond was likely to stabilize the MS2 antibody without negatively impacting antigen binding.
A construct containing S49C and I69C V H substitutions was made in the context of APE556 (APE565 ; Table I ), and analyzed by DSC. This modification resulted in a 5.98C improvement in Fab T m , such that the Fab and C H 3 domains now unfolded in a single melting transition (Fig. 4b) . Biacore binding analysis not only confirmed complete retention of MS2 antigen-binding affinity, but revealed a 4-fold further improvement in K D over APE556 (Table I ).
Stabilization of the C H 2 constant domain. The IgG1 C H 2 is the least stable domain of the MS2 antibody, typically unfolding with a T m in the 68-698C range (Fig. 2) . In order to improve C H 2 stability, and to assess the impact of C H 2 stabilization on the thermostability of neighboring domains, a disulfide bond was introduced into the anti-MS2 C H 2 (APE713). This disulfide bond incorporated L12C and K104C substitutions, previously shown to be stabilizing in the context of an isolated C H 2 domain (Gong et al., 2009) . DSC analysis demonstrated an 8.78C increase in C H 2 T m upon addition of this disulfide bond (compare T m 1 of APE556 and APE713, Fig. 4c ). Interestingly, stabilizing the C H 2 domain resulted in a 1.7 and 0.58C increase in respective Fab and C H 3 T m .
Computational design
Computational structure-based design offers a powerful tool to predict potentially stabilizing mutations within an antibody, providing a complement to knowledge-based engineering approaches. V H and V L sequences from the CDR-grafted anti-MS2 antibody were aligned to antibody structures in the RCSB Protein Databank in order to identify high-resolution, homologous structures for use in the design process. Two structures were chosen for the V H , PDB ID 3KDM and 2VXS; each is 97% identical to the MS2 antibody V H excluding the CDRs. Three homologous light chain structures were similarly chosen (PDB ID 1T66, 1HPO and 2H1P). These structures served as inputs for the design. The Rosetta suite of protein design software was used to further improve the stability of the anti-MS2 V H and V L domains using the homologous structures identified above (Kuhlman and Baker, 2000) . Potentially stabilizing amino acid substitutions were sampled in an iterative Metropolis Monte Carlo search, utilizing the backbone coordinates from each model structure and side-chain rotamer conformations taken from the Dunbrack backbone-dependent rotamer library (Dunbrack and Cohen, 1997) . CDR residues were excluded from the search in order to identify potentially stabilizing mutations more likely to be broadly applicable across multiple specificities, and to minimize the impact on antigen binding. Native Cys residues crucial to variable domain stability were also excluded from the design. The remaining 65% of V H and V L framework residues were allowed to change to all amino acids except for Cys. On average, 52% of the residues subject to redesign were mutated from the wild-type sequence; this is similar to results seen previously with this design method (Kuhlman and Baker, 2000; Dantas et al., 2003; Korkegian et al., 2005) .
Mutations identified by computational design were chosen for testing based on combined criteria including design score, frequency of a particular mutation in multiple design runs, and mutations that promoted optimal packing within the hydrophobic core (Korkegian et al., 2005) . Site-directed mutagenesis was used to generate a total of 10 heavy chain variants containing one or more amino acid substitutions. Two of the heavy chain mutations, L5V (þ0.68C) and R19I (þ0.38C), were found to be stabilizing when assessed by Thermofluor assay (Supplementary Table SI) . Of the nine combinations of light chain mutations tested, only the P12A, T14L double-mutant was significantly stabilizing, giving a 1.58C increase in Fab T m (Supplementary Table SII ). The remaining mutations tested had either a neutral or negative impact on stability.
The four stabilizing mutations identified by computational design were combined into a single-antibody construct, APE1032, in the context of the intra-V H disulfide bond. These new mutations gave an additive 3.88C improvement in Fab T m by DSC (Table I ; Fig. 5a ). Notably, this T m increase was 1.48C greater than was expected based on previous analysis of the individual mutations. 
Extreme thermostabilization and affinity maturation of an antibody
Consensus design
A proven approach to consensus design for stability is to compare a given variable region sequence to the consensus sequence for the most stable variable region family. While V H 3 is both the most common and the most stable of V H domains, this is not true for V k 2 (Knappik et al., 2000) . A comparison of V k 2D -30 to the consensus sequence of the most stable V L domain, V k 3, identified residue M4 as different from the consensus L4 (Supplementary Fig. S2 ). In addition, mutation of residue 4 in the light chain from Met to Leu has been shown to be stabilizing in multiple antibody contexts (Benhar and Pastan, 1995) . This residue is part of the hydrophobic core of the antibody where internal Met-to-Leu substitutions are known to improve hydrophobic core packing (Gassner et al., 1996) . The M4L substitution was incorporated into the stabilized MS2 antibody, giving a further 2.18C improvement in T m (APE1025, Table I ).
Biophysical characterization of combined stabilized antibody
A combined construct, APE979, was made to test the impact of incorporating the stabilized C H 2 domain into the context of the stabilized Fab domain. This increased the C H 2 T m to 84.58C, a 15.18C improvement relative to the initial CDR-grafted antibody (compare Figs 4c and 5b) . The combined antibody additionally exhibited a 0.78C and 4.38C increase in respective Fab and C H 3 melting temperatures upon incorporation of the stabilized C H 2 into APE1025 (Fig. 5) . Interestingly, the total calorimetric heat change of unfolding (DH) for this antibody (DH ¼ 3.97 Â 10 5 kcal) was reduced by 40% relative to the original CDR-grafted construct, APE443 (DH ¼ 6.65 Â 10 5 kcal). This is indicative of an increase in cooperativity of thermal unfolding for all three antibody domains. Final T m improvements relative to the starting CDR-grafted antibody were 15.18C (C H 2), 20.98C (Fab) and 4.38C (C H 3) (Fig. 5) . A non-exhaustive test of alternate buffer formulations identified a histidine-based buffer, pH 7.0, further improved the Fab T m by nearly 2 to 928C. Biacore binding analysis confirmed that the APE979 antibody not only maintained full antigen-binding activity, but exhibited a 30-fold improvement in MS2 affinity relative to the original CDR-grafted antibody (Table I) . Affinity improvement resulted from a 10-fold improvement in k a and a 3-fold improvement in k d .
To further assess the extent of APE979 stabilization, a panel of progressively stabilized MS2 antibody variants was subjected to a 1-h thermal challenge at high temperature. Heat-treated samples were analyzed for MS2 antigen-binding activity by Biacore (Fig. 5d) . APE979 was found to be the most stable antibody, maintaining .60% activity after 1 h at 898C. In contrast, both the scFv and the initial CDR-grafted antibody, APE443, showed a complete loss in activity after one hour at 708C.
The conformation of the IgG Fc region, and particularly the lower hinge/C H 2, is important for Fc gamma receptor binding and the elicitation of antibody effector function. Therefore, we tested binding of the combined, stabilized antibody APE979, to the high-affinity Fc gamma receptor, CD64 (Van de Winkel and Capel, 1993) . Stabilized APE979 exhibited no loss in CD64 binding in comparison to the starting antibody, APE443, and to a positive control antibody with known effector function ( Supplementary Fig. S1 ).
Affinity maturation
Affinity maturation of the anti-MS2 antibody was carried out in parallel in order to demonstrate the compatibility of affinity maturation with the stabilized antibody framework. A stably transfected HEK293 cell line expressing the V H /V L -optimized APE556 on the cell surface was generated for affinity maturation by AID-induced somatic hypermutation in vitro using the mammalian cell display system described (Bowers et al., 2011) . This antibody exhibited a 3-fold improvement in MS2-binding affinity relative to the initial CDR-grafted antibody, APE443 (Fig. 3) . The stable cell line was analyzed by flow cytometry to confirm simultaneous IgG expression and binding to Dylight-649-labeled MS2 antigen. After induction of somatic hypermutation via expression of AID, cells expressing higher-affinity variants of the starting antibody were isolated by FACS using iteratively decreasing concentrations of MS2-Dylight-649 (rounds 1-2) or MS2-WFP-DyLight-649 (all rounds subsequent to round 3) for increased stringency (Fig. 6a) . Sequence analysis after each round of antigen selection identified enriching mutations for downstream kinetic characterization. Two enriching mutations were observed in the heavy chain of APE556: A23V and F59S. The A23V substitution was located in the framework 1 region immediately adjacent to the first CDR loop, and F59S was just outside of the CDR2 (Fig. 7) .
To test the incorporation of SHM diversity into the light chain CDRs, four small libraries were constructed in which the most frequent light chain SHM changes were included; each library consisted of 100 variants ( Supplementary  Fig. S3 ). After mammalian cell expression, Biacore screening identified an antibody containing a triple mutant light chain with Q27E, S27eT and H93R substitutions that gave a 6.4-fold improvement in K D over APE556 (see APE1052 in Fig. 6b ). The affinity of this antibody was improved 13.5-fold over APE556 when combined with the F59S heavy chain mutation to make APE849. Recombining all five mutations in the context of the optimized V H /V L interface to make APE850 resulted in a final affinity for MS2 antigen of 985 pM ( Fig. 6b ; Table I ). The combination of interface optimization and in vitro SHM for affinity maturation together contributed to the final 85-fold improvement in K D over the initial grafted antibody, APE443, with a 12-fold improvement in k a and a 7-fold improvement in k d (Fig. 8) .
Grafting mature CDRs onto the stable IgG framework
In order to combine stability with increased binding affinity, affinity maturing mutations from APE850 were incorporated into the stabilized framework to make APE1027 ( Supplementary Fig. S4 ). Binding analysis by Biacore revealed a slight improvement in MS2 binding relative to the affinity-matured antibody with a K D of 880 pM; a final 95-fold improvement in K D relative to the starting IgG, APE443. In addition, the grafted antibody completely maintained stability with a Fab T m over 908C, though there was a slight reduction (,18C) in C H 2 and C H 3 T m (Fig. 7) . 
Discussion
The aim of this study was to establish a highly stabilized antibody scaffold while maintaining the ability to control antigen binding affinity. Such a scaffold could potentially expand the use of antibodies in therapeutic and industrial applications where high stability and affinity are required. This work advances upon previously reported methods of antibody stabilization to further demonstrate the advantage of an approach that encompasses multiple techniques including rational and computational design (Worn and Pluckthun, 1999; Monsellier and Bedouelle, 2006; Garber and Demarest, 2007) . Our final stabilized antibody has a T m over 908C and is, to our knowledge, the most stable full-length antibody reported to date. By avoiding mutations to the antigenbinding CDR loops, this antibody was additionally able to maintain full antigen-binding activity. In parallel, the starting antibody, APE443, was affinity matured to improve its K D by 85-fold through a combination of interface optimization and in vitro somatic hypermutation (Bowers et al., 2011) . Incorporating the mature mutations into the stabilized scaffold resulted in a highly stable, high affinity antibody with a 95-fold improved K D and a 218C increased Fab T m relative to the starting IgG, APE443. Our stable scaffold will potentially be useful in improving the biophysical characteristics of other antibodies, and is compatible with affinity maturation in the likelihood that affinity is lost in the grafting process.
Improved stability through rational design
Knowledge-based methods have previously been applied to improve antibody stability, including CDR grafting onto stable frameworks (Jung et al., 1999) and consensus-design (Ewert et al., 2003a (Ewert et al., , 2004 . Our first step towards stabilization was to graft specificity from the initial, mouse anti-MS2 scFv onto known stable human frameworks. Previous work has demonstrated the improvement in stability and affinity achieved through CDR grafting from a murine framework into stable human frameworks of similar structural subtype (Jung and Pluckthun, 1997; Jung et al., 1999) . However, our initial grafted antibody was only marginally improved in stability relative to the scFv, and displayed some loss in antigen binding affinity. Antibody framework residues can make significant contributions to the affinity of an antibody by affecting both the relative orientation of V H and V L domains and the positioning of antigen-binding CDR loops (Ewert et al., 2004) . In fact, the most strongly conserved amino acid networks in antibody variable domains occur within the interface between the V H and V L (Wang et al., 2009) . Preserving the variable region dimer interface in the CDR grafting process can even allow specificity grafting into more divergent antibody frameworks (Worn et al., 2000) . Restoring optimal V H and V L positioning to the grafted anti-MS2 antibody resulted in a complete restoration of affinity and increased the T m by a considerable 88C over the initial graft. This underscores the importance of the V H /V L interface in antibody stability and activity.
Consensus design was employed to identify further stabilizing mutations in the CDR-grafted anti-MS2 antibody. Residues that differ from the consensus for a given gene sequence are likely to be destabilizing in the absence of positive selection for increased thermodynamic stability.
It follows that mutation back to the consensus should, in most cases, be stabilizing. The consensus method has been applied to improve the stability of CDR-grafted antibodies as well as other proteins (Steipe et al., 1994; Chowdhury et al., 1998) . Here, consensus design identified a single stabilizing mutation in the anti-MS2 antibody, V L M4L. This mutation has previously been shown to be stabilizing in multiple antibody contexts (Benhar and Pastan, 1995) , and similar M to L substitutions have been demonstrated to be generally stabilizing in other proteins (Gassner et al., 1996) . While this light chain mutation was significantly stabilizing, a more rigorous comparison of the anti-MS2 light chain to the stable consensus V k 3 sequence may reveal additional stabilizing mutations. The intrinsic stability of V H 3 -23 limited our application of this method to the anti-MS2 heavy chain. Consensus design will be more useful in applications where a less common and/or less stable variable region framework is required.
Intra-domain disulfide bonds
The anti-MS2 antibody was additionally stabilized by incorporation of a non-native intra-domain disulfide bond into the V H . Disulfide bonds are thought to stabilize proteins by lowering their conformational entropy compared with the unfolded state (Zhang et al., 2011) . However, engineered intra-domain disulfide bonds are limited by their potential to disrupt other essential interactions within a given protein that can lead to an overall destabilization (Pecher and Arnold, 2009) . Antibodies are naturally stabilized by highly conserved intra-domain disulfides in each of their domains, including the V H . An antibody lacking this conserved intra-V H disulfide was shown to be significantly destabilized in comparison (Langedijk et al., 1998) . Conversely, addition of a second such disulfide has been demonstrated to increase thermal stability in the case of isolated V HH domains (Saerens et al., 2008) . Combining this knowledge together with computational methods, we identified a position buried within the anti-MS2 V H framework that could accommodate a second disulfide bond without affecting overall CDR loop positioning or heavy and light chain orientation. Indeed, mutation of V H S49 and I69 residues to Cys dramatically increased the anti-MS2 Fab T m without negatively impacting affinity; likely due to the fact that these mutations resulted in a disulfide bond that was buried within the IgG fold and did not affect CDR loop positioning. Similarly placed intra-V H disulfide bonds are likely to be stabilizing in multiple human antibody contexts.
Following similar logic, engineering a disulfide bond into the C H 2 IgG1 constant domain of the anti-MS2 antibody increased the C H 2 T m by a full 158C when combined with the fully stabilized Fab. This disulfide bridge linked L12C to K104C within the C H 2, and was previously shown to be similarly stabilizing within an isolated C H 2 domain (Gong et al., 2009) . Remarkably, addition of this C H 2 disulfide bond also had an indirect stabilizing effect on the Fab and C H 3 domains. This suggests a highly cooperative effect of antibody domain stabilization, contrary to previous hypotheses that independent unfolding of the C H 2, C H 3 and Fab domains is a general property of IgGs (Vermeer and Norde, 2000; Demarest et al., 2006) . Again, this disulfide bond did not negatively impact functional activity of the antibody.
These data further emphasize the utility of well-placed disulfide bonds in increasing protein stability.
While this study demonstrates the effective use of disulfide bonds to improve the stability of an antibody, this may not be compatible with all antibody formats and expression systems. This includes expression in reducing environments such as the prokaryotic cytoplasm as well as other intracellular applications. In such cases, the disulfide bonds may be removed from the stable scaffold, and other engineering approaches applied to restore the desired stability.
Predicting stabilizing mutations through computational design
Structure-based computational design was employed to complement the above rational engineering methods by predicting stabilizing mutations within the anti-MS2 V H and V L domains. Two of the predicted V H point mutations tested were significantly stabilizing, L5V and R19I. Similarly, one pair of V L mutations, P12A/T14L, gave a notable improvement in T m . These are consistent with previous results reported using the fixed backbone design mode in RosettaDesign; substitutions that increase the number of hydrophobic residues within a protein are most likely to be stabilizing (Dill, 1990; Korkegian et al., 2005) . The burial of hydrophobic groups is one of the driving forces of protein folding . In this study, design predictions incorporating or changing residues with polar or charged residues were less successful, and none of these mutations resulted in improved stability (e.g. L5D in the heavy chain reduced T m by 2.28C). This was likely due to the difficulty of accurately modeling hydrogen bonding within proteins. In addition, the clustered V H substitutions predicted by RosettaDesign were all destabilizing to the anti-MS2 antibody. These larger substitutions, predicted in the isolated V H domain context, may disrupt important stabilizing interactions within the overall antibody.
The complex multi-domain structure of IgGs makes their structure-based design difficult, especially in the absence of a high-resolution crystal structure. While this method was useful in identifying some stabilizing mutations within the anti-MS2 V H and V L domains, it may be possible to increase the accuracy of these predictions in the future by generating improved input structures for the design. The current study utilized homologous crystal structures and modeled stabilizing mutations on isolated V H and V L domains. More accurate results may be obtained either by generating full homology models of the V-region of interest, or by solving the crystal structure. Future stability designs should also analyze the full V-region as a whole in order to avoid mutations that directly or indirectly disrupt the domain interface.
Protein expression and stability
While some correlation between thermal stability and protein expression levels has been observed for various antibody formats expressed in Escherichia coli, similar correlations have not been observed in mammalian expression systems (Demarest et al., 2006; Schaefer and Pluckthun, 2012) . Except for the anti-MS2 scFv, all antibodies used in this project were expressed as full-length IgGs in mammalian cells. These antibodies were well expressed, yielding 100 mg/L when stably expressed in CHO-S cells. While the scFv did exhibit significant aggregation propensity, all full-length antibodies expressed throughout the study were highly soluble. Previous studies have also shown that antibodies selected using mammalian cell display with HEK-293 cells retain high expression levels when expressed in CHO cells (Bowers et al., 2011) .
Affinity maturation and the stabilized scaffold
In the present example, a 30-fold improvement in antigenbinding affinity was observed as a by-product of the stabilization process. Some of the affinity improvement was accounted for by restoring the antibody dimer interface after CDR grafting, but a further 11-fold relative improvement in K D was observed in the final stabilized antibody, APE979. The incorporated mutations likely stabilize the antibody in a conformation that is more conducive to antigen binding, and this is suggestive of a close connection between antibody stability and affinity. In addition, the stabilized antibody showed no loss in FcgRI receptor binding, further indicating that this antibody retains functionality.
Loss in affinity for antigen is a known consequence of CDR grafting (Queen et al., 1989) . To begin investigating the feasibility of incorporating variant CDR loop sequences into the stabilized antibody scaffold, the initial anti-MS2 antibody was affinity matured to an 85-fold improved K D , and the mature mutations added back onto the stabilized scaffold. The resulting combined antibody not only maintained a Fab T m of over 908C, but exhibited an even further improved affinity for the MS2 antigen. This observation provides evidence that the CDR loops have little impact on the biophysical properties of the stabilized scaffold, and suggests that CDR loops of more divergent specificity may be able to be grafted into this scaffold without loss in stability. It also demonstrates the compatibility of the stabilized scaffold with affinity maturation in cases where the desired affinity is lost in the grafting process or higher affinity is desired. It is interesting to note that the mature mutations resulting from SHM in vitro impacted MS2 binding affinity differently when incorporated into the interface-optimized antibody, APE556 (improved K D 27-fold) versus the stabilized antibody, APE 979 (improved K D 3-fold). APE979 itself displayed an 11-fold improved K D relative to APE556, and it is possible that there is some redundancy in the impact of stabilizing and affinity maturing mutations on MS2-binding affinity. It is also possible that some of these mutations are not compatible with respect to antigen binding. Future work will explore the feasibility of grafting CDRs from more divergent antibodies into the stabilized scaffold generated here.
Conclusions
In conclusion, we have described the advantages of a combinatorial approach that comprises rational and computational engineering to improve the biophysical characteristics of an antibody, and demonstrated its usefulness in generating a highly stable antibody capable of withstanding thermal challenge up to 908C. Notably, mutations identified by each method employed were either additively or synergistically stabilizing, resulting in an improved cooperativity of thermal unfolding in all domains. This underscores the benefit of using a variety of techniques in the stabilization of a single protein. Mutations from an affinity-matured variant of the starting antibody were incorporated into the stabilized framework with full retention of stability and improved affinity.
This IgG framework has the broader potential to serve as an extremely stable scaffold onto which multiple other specificities may be grafted. Paired with the affinity maturation approach described, this should enable the rapid development of highly stable high-affinity antibodies.
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